news
Cannabidiol identified as potential ‘helper’ compound for antibiotics
Researchers have found that using antibiotics in combination with cannabidiol (CBD) enhanced their effect against Staphylococcus aureus bacteria.
List view / Grid view
Therapeutics
article
Expert view: Are you ready for next generation therapeutic antibodies?
Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.
article
TCR therapy – an attractive alternative to CAR T
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
news
Chronic use of heart disease medications may increase the risk of severe COVID-19
A researcher has revealed that angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) may increase the risk of severe lung complications in COVID-19.
news
UK Consortium to monitor spread and behaviour of coronavirus
The UK government has invested £20 million into the COVID-19 Genomics UK Consortium, which will use whole genome sequencing to inform infection control measures and therapeutic developments.
article
Antibodies In-Depth Focus 2020
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
news
COVID-19 research hub: promoting scientific collaboration
Drug Target Review has created a COVID-19 research hub with forum space for discussions and a place to share your research - plus all of our articles and news.
news
Researchers to screen compound library for antiviral drugs to combat COVID-19
Scripps Research has announced it will screen over 14,000 compounds to see if any present significant activity against COVID-19, for use in a therapeutic.
article
Drug Target Review – Issue 1 2020
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
article
Targeted protein degradation: the next wave of therapeutics
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
news
Novel phage display technique could lead to new peptide-based therapeutics
Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.
news
Gene therapy could cure Danon disease, life-threatening genetic condition
Researchers have shown a gene therapy to correct the genetic mutation that causes Danon disease is successful in pre-clinical trials.
news
Collaboration to co-develop antibody products for treating COVID-19
AbCellera and Eli Lilly have announced their partnership to develop, manufacture and distribute antibody treatments for the COVID-19 coronavirus.
news
Drug candidate stops tumour growth with little toxicity in mice
A star-shaped molecule along with a modified platinum drug have demonstrated success at combatting tumours with few toxic effects in mice.
news
Software able to screen up to 1.4 billion compounds developed
New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.
